AUTHOR=Xie Yue-liang , Jin Xin , Yan Shan-shan , Wu Cui-fang , Xiang Bi-xiao , Wang Hui , Liang Wu , Yang Bing-chang , Xiao Xue-fei , Li Zhi-ling , Pei Qi , Zuo Xiao-cong , Peng Yue 

TITLE=Population pharmacokinetics of intravenous colistin sulfate and dosage optimization in critically ill patients

JOURNAL=Frontiers in Pharmacology

VOLUME=13

YEAR=2022

URL=https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2022.967412

DOI=10.3389/fphar.2022.967412

ISSN=1663-9812

ABSTRACT=<p><bold>Aims:</bold> To explore the population pharmacokinetics of colistin sulfate and to optimize the dosing strategy for critically ill patients.</p><p><bold>Methods:</bold> The study enrolled critically ill adult patients who received colistin sulfate intravenously for more than 72 h with at least one measurement of plasma concentration. Colistin concentrations in plasma or urine samples were measured by ultraperformance liquid chromatography tandem mass spectrometry (LC-MS/MS). The population pharmacokinetics (PPK) model for colistin sulfate was developed using the Phoenix NLME program. Monte Carlo simulation was conducted to evaluate the probability of target attainment (PTA) for optimizing dosing regimens.</p><p><bold>Results:</bold> A total of 98 plasma concentrations from 20 patients were recorded for PPK modeling. The data were adequately described by a two-compartment model with linear elimination. During modeling, creatinine clearance (CrCL) and alanine aminotransferase (ALT) were identified as covariates of the clearance (CL) and volume of peripheral compartment distribution (V2), respectively. In addition, colistin sulfate was predominantly cleared by the nonrenal pathway with a median urinary recovery of 10.05% with large inter-individual variability. Monte Carlo simulations revealed a greater creatinine clearance associated with a higher risk of sub-therapeutic exposure to colistin sulfate. The target PTA (≥90%) of dosage regimens recommended by the label sheet was achievable only in patients infected by pathogens with MIC ≤0.5 mg/L or with renal impairments.</p><p><bold>Conclusion:</bold> Our study showed that the dose of intravenous colistin sulfate was best adjusted by CrCL and ALT. Importantly, the recommended dosing regimen of 1.0–1.5 million units daily was insufficient for patients with normal renal functions (CrCL ≥80 ml/min) or those infected by pathogens with MIC ≥1.0 mg/L. The dosage of colistin sulfate should be adjusted according to renal function and drug exposure.</p>